Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions

Abhinav Sharma, Neha J. Pagidipati, Robert M. Califf, Darren K. McGuire, Jennifer B. Green, Dave Demets, Jyothis Thomas George, Hertzel C. Gerstein, Todd Hobbs, Rury R. Holman, Francesca C. Lawson, Lawrence A. Leiter, Marc A. Pfeffer, Jane Reusch, Jeffrey S. Riesmeyer, Matthew T. Roe, Yves Rosenberg, Robert Temple, Stephen Wiviott, John McMurrayChristopher Granger

Cardiology
Internal Medicine

Research output: Contribution to journal › Review article › peer-review

62 Scopus citations

Sort by
Weight
Alphabetically

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions

Fingerprint

Medicine & Life Sciences